Literature DB >> 22739778

Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012.

.   

Abstract

Since 2005, the Advisory Committee on Immunization Practices (ACIP) has recommended a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine booster dose for all adolescents aged 11 through 18 years (preferred at 11 through 12 years) and for those adults aged 19 through 64 years who have not yet received a dose. In October 2010, despite the lack of an approved Tdap vaccine for adults aged 65 years and older, ACIP recommended that unvaccinated adults aged 65 years and older be vaccinated with Tdap if in close contact with an infant, and that other adults aged 65 years and older may receive Tdap. In July 2011, the Food and Drug Administration (FDA) approved expanding the age indication for Boostrix (GlaxoSmithKline Biologicals, Rixensart, Belgium) to aged 65 years and older. In February 2012, ACIP recommended Tdap for all adults aged 65 years and older. This recommendation supersedes previous Tdap recommendations regarding adults aged 65 years and older.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22739778

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  34 in total

1.  Incidence of whooping cough in Spain (1997-2010): an underreported disease.

Authors:  María Isabel Fernández-Cano; Lluís Armadans Gil; Xavi Martínez Gómez; Magda Campins Martí
Journal:  Eur J Pediatr       Date:  2013-12-11       Impact factor: 3.183

2.  Assessment of Tdap administration rates from 2009 to 2012 at a large urban nonteaching hospital.

Authors:  Eric Wombwell; Whitney Palecek; Elizabeth Englin; Tinh Nguyen
Journal:  J Community Health       Date:  2014-02

3.  The Effect of Pharmacy-Driven Education on the Amount of Appropriately Administered Tetanus Vaccines in the Emergency Department.

Authors:  Meghan Fletcher; Shannon Rankin; Preeyaporn Sarangarm
Journal:  Hosp Pharm       Date:  2018-04-18

4.  Toward a new vaccine for pertussis.

Authors:  John B Robbins; Rachel Schneerson; Joanna Kubler-Kielb; Jerry M Keith; Birger Trollfors; Evgeny Vinogradov; Joseph Shiloach
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-20       Impact factor: 11.205

5.  Provider perspectives on multilevel barriers to HPV vaccination.

Authors:  Paige W Lake; Monica L Kasting; Shannon M Christy; Susan T Vadaparampil
Journal:  Hum Vaccin Immunother       Date:  2019-04-11       Impact factor: 3.452

Review 6.  Prevention of pertussis through adult vaccination.

Authors:  Manika Suryadevara; Joseph B Domachowske
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Using the 4 Pillars™ Practice Transformation Program to increase adult Tdap immunization in a randomized controlled cluster trial.

Authors:  Mary Patricia Nowalk; Chyongchiou J Lin; Valory N Pavlik; Anthony E Brown; Song Zhang; Krissy K Moehling; Jonathan M Raviotta; Jeannette E South-Paul; Mary Hawk; Edmund M Ricci; Donald B Middleton; Suchita A Patel; Faruque Ahmed; Richard K Zimmerman
Journal:  Vaccine       Date:  2016-08-26       Impact factor: 3.641

Review 8.  Pertussis re-emergence in the post-vaccination era.

Authors:  Elena Chiappini; Alessia Stival; Luisa Galli; Maurizio de Martino
Journal:  BMC Infect Dis       Date:  2013-03-26       Impact factor: 3.090

9.  National and State-Specific Td and Tdap Vaccination of Adult Populations.

Authors:  Peng-Jun Lu; Alissa O'Halloran; Helen Ding; Jennifer L Liang; Walter W Williams
Journal:  Am J Prev Med       Date:  2015-11-29       Impact factor: 5.043

10.  Tetanus, diphtheria and acellular pertussis (Tdap) vaccine for prevention of pertussis among adults aged 19 years and older in the United States: A cost-effectiveness analysis.

Authors:  Bo-Hyun Cho; Anna M Acosta; Andrew J Leidner; Amanda E Faulkner; Fangjun Zhou
Journal:  Prev Med       Date:  2020-03-19       Impact factor: 4.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.